博腾股份(300363) - 2022 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2022 reached ¥1,303,577,566.55, representing a 68.42% increase year-over-year[6]. - Net profit attributable to shareholders was ¥365,447,482.53, up 150.08% compared to the same period last year[6]. - The net profit after deducting non-recurring gains and losses was ¥365,491,661.64, reflecting a 141.15% increase year-over-year[6]. - The basic earnings per share (EPS) was ¥0.67, an increase of 148.15% from the previous year[6]. - Total revenue for the first nine months of 2022 reached CNY 5,217,592,886.95, a 157.05% increase compared to CNY 2,029,816,801.54 in the same period of 2021[16]. - Net profit for the first nine months surged to CNY 2,992,451,126.36, a 96.91% increase from CNY 1,519,689,348.80 in the previous year[16]. - The overall gross margin for the reporting period was 52.56%, an increase of 8.85 percentage points year-on-year[29]. - Operating profit for the period was ¥1,749,356,581.71, up from ¥389,327,250.60, reflecting a growth of 348.5% year-over-year[65]. - Net profit attributable to shareholders of the parent company was ¥1,577,785,680.52, compared to ¥360,700,820.85 in the previous year, marking an increase of 338.5%[65]. Assets and Liabilities - Total assets as of September 30, 2022, amounted to ¥10,147,132,892.55, a 54.63% increase from the end of the previous year[6]. - Total liabilities increased to ¥4,131,497,307.22 from ¥2,375,948,241.39, representing a growth of 73.8%[65]. - The company’s total assets reached ¥10,147,132,892.55, compared to ¥6,562,035,209.95, indicating a growth of 54.5%[65]. - The company’s inventory increased to RMB 1,078.96 million as of September 30, 2022, compared to RMB 757.39 million at the beginning of the year, reflecting a growth of 42.5%[58]. - The company’s accounts receivable increased to RMB 1,249.62 million as of September 30, 2022, compared to RMB 1,035.07 million at the beginning of the year, showing an increase of 20.7%[58]. Cash Flow - The company's cash flow from operating activities for the year-to-date reached ¥2,303,661,711.51, a significant increase of 819.16%[6]. - The net cash flow from operating activities for the current period is CNY 2,303,661,711.51, a significant increase from CNY 250,627,959.49 in the previous period[71]. - Cash inflow from operating activities totaled CNY 4,528,728,396.70, compared to CNY 1,989,701,745.37 in the prior period, reflecting a growth of approximately 127.4%[71]. - Cash flow from financing activities showed a significant increase, with cash received from borrowings reaching CNY 1,091,827,163.00, up 732.67% from CNY 131,124,079.81[16]. - The ending balance of cash and cash equivalents increased to CNY 2,880,227,808.05 from CNY 1,176,814,356.74, representing a growth of approximately 144.4%[71]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 42,176[19]. - The largest shareholder, Chongqing Liangjiang New Area Industrial Development Group Co., Ltd., holds 14.51% of shares, totaling 78,982,719 shares[19]. - The second-largest shareholder, Ju Nianfeng, owns 10.82% of shares, amounting to 58,890,521 shares, with 44,167,891 shares pledged[19]. - The company has a total of 10 major shareholders, with the top 10 holding a significant portion of the shares[19]. - The report confirms that the top 10 shareholders do not participate in margin financing[19]. Research and Development - The company’s R&D expenses rose to CNY 450,657,966.94, a 101.53% increase from CNY 223,621,085.82, reflecting ongoing investment in technology and product development[16]. - Research and development expenses amounted to ¥450,657,966.94, which is an increase of 101.9% from ¥223,621,085.82 in the same period last year[65]. Investments and Acquisitions - The company acquired 100% equity of Kaihui Pharmaceutical (Shanghai) Co., Ltd., contributing to a 94.14% increase in intangible assets[9]. - The company is expanding its CDMO factory and other projects, leading to a 137.07% increase in construction in progress[9]. - The company is investing 50 million euros to build a small molecule R&D and production base in Slovenia, expected to be operational by September 2024[46]. - The company has approved a B-round financing for its subsidiary, Suzhou Boteng Biopharmaceutical Co., Ltd., amounting to RMB 52 million, with external investors contributing RMB 40 million[54]. Tax and Expenses - The company’s tax expenses surged to CNY 227,580,076.54, a 596.89% increase from CNY 32,656,561.35, driven by higher profitability[16]. - The company paid taxes amounting to CNY 383,809,619.26, significantly higher than CNY 132,106,842.11 in the prior period, indicating an increase of about 189.5%[71].